Federal prosecutors are expected to file drug and weapons charges against Brent Matthew Wilson, the original bass guitarist for Panic! at the Disco, the musician’s lawyer told a Las Vegas judge on Wednesday.
Federal prosecutors are expected to file drug and weapons charges against Brent Matthew Wilson, the original bass guitarist for Panic! at the Disco, the musician’s lawyer told a Las Vegas judge on Wednesday.
PHOENIX, March 05, 2021 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), (TSX: GWR), a pure-play water resource management company, has been invited to present at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside chats. Past events have featured more than 550 participating companies and drawn more than 5,000 attendees, including institutional investors, analysts, family offices and high-net-worth investors. Management will participate in one-on-one meetings with investors and analysts during the conference and will discuss the company’s recently reported results for 2020, with revenue up 8.9% to $38.6 million driven largely by increased connections, water consumption and higher rates. Management will also discuss the company’s continued focus on consolidating, improving and automating water and wastewater utilities through its active M&A program, including plans for additional ‘tuck-in’ acquisitions over the next year. To submit a registration request, click here. To schedule a one-on-one meeting with Global Water Resources, please contact your ROTH representative. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here. About ROTH Capital PartnersROTH Capital Partners, LLC “ROTH” is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately held and employee owned. For more information on ROTH, please visit www.roth.com.About Global Water ResourcesGlobal Water Resources, Inc. is a leading water resource management company that owns and operates 16 utilities which provide water, wastewater, and recycled water services. The company’s service areas are located primarily in growth corridors around metropolitan Phoenix. Global Water recycles nearly 1 billion gallons of water annually. The company has been recognized for its highly-effective implementation of Total Water Management (TWM), an integrated approach to managing the entire water cycle by owning and operating water, wastewater and recycled water utilities within the same geographic area to maximize the beneficial use of recycled water. TWM conserves water by using the right water for the right use and helps protect water supplies in water-scarce areas experiencing population growth. To learn more, visit www.gwresources.com. Cautionary Note Regarding Forward-Looking Statements This press release includes certain forward-looking statements which reflect the company's expectations regarding future events. The forward-looking statements involve a number of assumptions, risks, uncertainties, and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning future net income growth, our strategy, acquisition plans and our ability to complete additional acquisitions, our dividend policy, trends relating to population growth, active service connections, regulated revenue, housing permit projections, the development of residential and commercial properties within our service areas, the anticipated impacts from the COVID-19 pandemic on the company, including to our business operations, results of operations, cash flows, and financial position, and our future responses to the COVID-19 pandemic, the success of our rate application and the timing of any resulting phase-in of new rates, and other statements that are not historical facts as well as statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", or the negative of these terms, or other words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to a number of risks, uncertainties, and assumptions, most of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from these expectations due to changes in political, economic, business, market, regulatory, and other factors, including the duration and severity of the COVID-19 pandemic and the actions to contain the virus or treat its impact, such as the efficacy of vaccines (particularly with respect to emerging strains of the virus). Accordingly, investors are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s views as of the date hereof. Factors that may affect future results are disclosed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our filings with the Securities and Exchange Commission (the "SEC"), which are available at the SEC's website at www.sec.gov. This includes, but is not limited to, our Annual Report on Form 10-K for the year ended December 31, 2020 to be filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, except as required by law, whether as a result of new information, future developments or otherwise. Company Contact:Michael Liebman CFO and SVPTel (480) 999-5104 email@example.com Investor Relations Contact:Ron Both or Grant StudeCMA Investor RelationsTel (949) 432-7566Email contact
Cocktail Sneakers®, an elevated casual footwear brand that is redefining sneaker culture for women™, today launched two (2) new designs, adding to its collection of classic slip-on and lace-up options.
The U.S. economy likely added back the most jobs since November last month, as easing COVID-19 case counts and a ramping vaccine rollout allowed distancing restrictions to begin to moderate.
Meghan previously accused 'the Firm' of 'perpetuating falsehoods' about her.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that Company management will participate in the upcoming H.C. Wainwright Global Life Sciences Conference taking place virtually from March 9-10, 2021.
SAN DIEGO, March 05, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company") announces today that after months of negotiation and diligence, it has closed the acquisition of certain assets of Primordia, a seed-to-soil, single-origin hemp supply company (https://www.primordia.eco/), with a combination of cash and other future rights and entitlements. Primordia will continue with its remaining operations under a different name but will not compete with Green Hygienics in this sector. The assets include inventory, equipment, brands and trademarks, an e-commerce site and customer base, as well as relationships that will provide a significant capacity for large-scale cultivation of over 10,000 acres of legacy farmland. “We are at the forefront of a growing, dynamic new sector within the biotech industry. The demand side continues to grow rapidly, while on the supply side the learning curve is steep and opportunities for valued acquisitions will arise,” said Green Hygienics CEO Ron Loudoun. “Our first e-commerce site is for the boutique brand Sol Valley Ranch, and the Primordia acquisition will target farm-direct bulk wholesale buyers. When you consider the improved ROI created through sales of finished product, it makes sense to develop or acquire a portfolio of e-commerce sites that target specific market segments. This acquisition will generate immediate cash flow for Green Hygienics.” About Primordia In 2019, Primordia announced its official launch into the rapidly growing industrial hemp and CBD market with over 10,000 acres of legacy farmland and infrastructure ideal for hemp cultivation in the Imperial Valley. The company benefits from a 365-day cultivation window and has developed proprietary hemp strains tailored for the region alongside integrated post-processing and extraction facilities. The first crop was granted USDA Certified Organic status. Since its inception, Primordia has grown over 2,000 acres of industrial hemp in the Imperial Valley of California and has produced a wide range of derivatives for the burgeoning cannabinoid market. The business is vertically integrated, with operations on-site including genetic development, seed propagation, cultivation, harvesting, drying, milling, testing and extraction. The company is now selling multiple products, including broad spectrum THC-free distillate, CBD isolate, water soluble extracts, viable high-CBD seed, certified organic biomass and winterized crude, and it is also taking custom orders for finished products like tinctures and topical lotion. For more information, visit https://www.primordia.eco/. About Green Hygienics Holdings Green Hygienic Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”) is a California-based innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids. The Company’s corporate mission is to adhere to the highest standards of operations in consistently delivering safe and premium-quality products to consumers as well as to partner with CPG (consumer packaged goods) and pharmaceutical companies. The Company intends to be a leader in compliances and capabilities in the hemp and cannabinoid supply marketplace. Using state-of-the-art technologies, Green Hygienics intends to open a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability. We are building a team of visionary agrotechnology, pharmaceutical and life scientists working at the intersection of nutraceutical, cosmeceutical and pharmaceutical technologies with a goal to improve lives. Hygienics is the science of preserving and promoting the health of individuals, communities and the planet. For further information about Green Hygienics Holdings Inc., please visit the Company’s website at: www.greenhygienics.com Follow us on: Facebook, Twitter and Linkedin View our corporate video: here. Corporate Communications: Heidi Thomasen Thomasen Communications IR@GreenHygienics.com Toll Free 1.855.802.0299 CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTSThis document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Public Relations: InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com
BURLINGAME, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences in March: The first conference will be the H.C. Wainwright Global Life Sciences Conference, which is taking place March 9-10, 2021. The Company will conduct one-on-one meetings with institutional investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on Tuesday, March 9.The second conference will be the 33rd Annual Roth Virtual Conference, which is taking place March 15-17, 2021. Dr. Miller will participate in a fireside chat at 2:30 pm ET / 11:30 am PT on Tuesday, March 16 and the Company will conduct one-on-one meetings with institutional investors at the conference. In addition, a pre-recorded corporate overview presentation by Dr. Miller will be made available beginning on Monday, March 8, 2021. A webcast of the presentations and the fireside chat noted above will be available via the investor relations section of the Corvus website and replays will be available for 90 days following the events. About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+firstname.lastname@example.org MEDIA CONTACT:Sheryl SeapyW2O email@example.com
Dr. Cuzzocrea’s Appointment Expands the Company’s Expertise in Field of Nitric Oxide TherapeuticsSAN FRANCISCO and TORONTO, March 05, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced the addition of Professor Salvatore Cuzzocrea, Ph.D. as an independent member of the Company’s board of directors (the “Board of Directors”), effective immediately. Dr. Cuzzocrea is an acknowledged expert in the science and clinical use of nitric oxide therapy, and his appointment to the Board of Directors will position the Company as a leader in the field of nitric oxide therapeutics. “We are delighted to add Dr. Cuzzocrea to the Company’s Board of Directors,” stated Robert Farrell, President and CEO. “We are eager to begin work with Dr. Cuzzocrea on development of R-107, our proprietary nitric oxide releasing compound that is being developed as a treatment for coronavirus, vaccine-resistant COVID-19, and other viral infections. With his deep experience and knowledge regarding nitric oxide and R-107, he will be a strong strategic resource for Claritas. We look forward to the contributions he will make.” Nitric oxide has been demonstrated to be effective against a wide variety of viruses. Nevertheless, nitric oxide has not been developed as an antiviral agent due to the fact that it is a gas that must be administered by inhalation therapy, which requires special inhalation equipment and administration by trained respiratory therapists. R-107 is a liquid, nitric oxide releasing compound designed to overcome these issues. R-107 can be easily administered orally as a capsule, or nasally through use of a nasal spray, or by injection. Claritas will not only develop R-107 as a therapy for vaccine-resistant COVID-9 infection, but also as a broad-spectrum antiviral drug for the treatment and possible prevention of future viral outbreaks, including viruses that cause influenza and the common cold. Dr. Cuzzocrea, the former President of the European Shock Society, is an internationally renowned authority and leader on the biology and pathophysiology of nitric oxide. He currently serves in numerous leadership roles at the University of Messina in Sicily, including Director of Scientific Research, Director of the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Director of the Oncology Unit at the University Hospital of Messina, and Full Professor of Pharmacology at the University’s School of Medicine. Dr. Cuzzocrea has been awarded honorary Professorships in Pharmacology at the University of Manchester and Saint Louis University, was elected a Fellow of the British Pharmacological Society, and has been appointed as an Honorary Lecturer in Pharmacology at the Department of Experimental Medicine and Nephrology at The William Harvey Institute at St. Bartholomew’s and Royal London School of Medicine and Dentistry. In 2020, Professor Cuzzocrea was elected Vice-President of the Board of the Conference of Rectors of all Italian universities. Dr. Cuzzocrea received his undergraduate and graduate medical education at the University of Messina, followed by doctoral studies at Cincinnati Children’s Hospital Medical Center and the William Harvey Institute in London. He is the author of more than 759 peer-reviewed publications and books, and is an international leader in the fields of autoimmunity, inflammation, toxic inhalational lung injury, and neurodegenerative disorders. Dr. Cuzzocrea’s research interests include the role of nitric oxide in the pathophysiology and treatment of pulmonary inflammation and cytokine storm associated acute lung injury, and the identification of new potential pharmacological targets for nitric oxide in autoimmune and inflammatory diseases. Dr. Cuzzocrea brings expert knowledge of R-107 to Claritas, having carried out more than 40 studies of this molecule in the treatment of experimental models of acute lung injury, pulmonary arterial hypertension, wound healing, ischemia-reperfusion injury, and multiple organ failure in sepsis and endotoxic shock. Dr. Cuzzocrea is an authority also on the biological mechanisms of cytokine-storm induced acute lung injury, and thus is ideally positioned to understand the pathophysiology of COVID-19 disease and its amelioration by supplemental provision of nitric oxide by administration of R-107. About Claritas PharmaceuticalsClaritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need, and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives. Website Home: https://claritaspharma.com/News and Insights: https://claritaspharma.com/news/Investors: https://claritaspharma.com/investors Cautionary StatementsNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives, and other statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavorable results. Claritas undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results (as applicable). Although Claritas believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Claritas’ control. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Claritas disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Contact InformationRobert FarrellPresident, CEO(888) firstname.lastname@example.org
OTTAWA, March 05, 2021 (GLOBE NEWSWIRE) -- Renewable Industries Canada (RICanada), representing business leaders in renewable fuel production and technology welcomes the opportunity to comment on Canada’s draft Clean Fuel Regulations (CFR). RICanada supports a national policy for cleaner fuels and believes an environmentally viable and economically realistic path to decarbonization by 2050 is possible provided policies, like the CFR, are well designed and properly implemented. As part of the multi-year CFR consultation, RICanada provided input to ensure the policy works for fuel producers, fuel suppliers, agriculture, and consumers. These contributions included recommendations from Canadian businesses, market leaders, economists, and subject matter experts to help ensure: the precise and effective measuring of fuels' carbon intensity, removing barriers for low carbon fuel blending and adoption, and fair recognition of sustainable agriculture practices. RICanada’s key recommendations to Environment and Climate Change Canada (ECCC) on the proposed regulation are: Maintain the proposed timeline with publication of final regulations by the end of 2021 and early action credit generation immediately upon publication of final regulations. The full regulations should come into force by December 2022.Release all available details of the ECCC Life Cycle Analysis model to enable early action by obligated parties and investments by low-carbon fuel producers.Reduce regulatory burden by confirming an aggregate recognition of U.S. and Canadian farming practices as sustainable. Simplify farm-level declarations in jurisdictions where there is aggregate recognition of sustainability.Remove barriers to blending higher levels of biofuel including ethanol (E15 – E85) and accelerate adoption of sustainable aviation fuel (SAF). About RICanada Founded in 1984, Renewable Industries Canada (RICanada) represents the producers and supporters of clean, renewable fuels. Committed to raising consumer awareness and policy building, we have been the leading, national voice for Canada's domestic biofuel industry for over 35 years. Our membership includes some of the largest and brightest biofuels producers, business innovators, agricultural leaders, and industry experts in the country For further information, contact: Dan Pfeffer, Renewable Industries Canada, email@example.com, T: 1-833-4-RN-FUEL, Twitter: @renewcan
First water sampling tests indicate good results TORONTO, March 05, 2021 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (the "Corporation" or "Doré Copper") (TSXV: DCMC; OTCQB: DRCMF; FRA: DCM) is pleased to announce its preparation plans for the dewatering of the former Joe Mann and Cedar Bay mines which closed in 2007 and 1990, respectively. The Company recently conducted water sampling tests down each shaft which returned positive results: Cedar Bay Mine Sampling (November 2020):The Cedar Bay mine ceased operations in 1990 after having produced 3.9 million tonnes (Mt) of ore grading 1.63% Cu and 3.21 g/t Au. Water was sampled down the shaft every 100 meters down to the deepest development level of 760 meters for a total of seven samples. Video inspection of the shaft indicated no deformation with rails intact and in place. The average pH was 6.52, mildly acidic or near neutral (pure water has a pH of 7.0). Heavy metals were low in concentration with many metals below detection limits. The characterization demonstrated the presence of dissolved solids that will also need to be considered in the selection of the water treatment system for dewatering. Joe Mann Mine Sampling (February 2021):The Joe Mann mine ceased operation in 2007 after having produced 1.2 million ounces of gold (4.75 Mt of ore grading 8.26 g/t Au and 0.25% Cu). Water was sampled down the shaft every 100 meters down to the deepest development level of 1,150 meters for a total of 12 samples. Video inspection indicated that the shaft is in excellent condition. The average pH was 7.35, indicating a slightly basic water chemistry. Heavy metals were low in concentration with many metals below detection limits. Copper and zinc concentrations were below detection limits in the majority of the samples. The characterization also demonstrated the presence of dissolved solids in this shaft, which will have to be considered in the choice of the water treatment system. Ernest Mast, President and CEO, stated: “We are greatly encouraged by the good condition of the shafts and benign water characteristics in both mines. Following completion of the dewatering assessment, we will be in a position to make a decision on the dewatering of these mines. The dewatering would provide Doré Copper underground access to the lowest levels of the mines and accelerate our exploration and development timeline while lowering our drilling costs and improving drilling accuracy.” Following the positive results of the water samples, Doré Copper will commence the design of the dewatering programs. This assessment will include the costs and timelines of the dewatering, water treatment process, final treated water destination and precipitate disposal for each mine. The work is expected to be completed by year-end. Concurrently with the assessment, the Corporation will be submitting in April an application for attestation of exemption (demande d’attestation de non-assujettissement) to the Québec Ministry of Environment and Fight Against Climate Change. Subject to this approval, the Company would proceed to the second step, which is the application to the regional MELCC under Article 22. It is expected that approval would be received within six to eight months. The Corporation contracted BluMetric Environmental Inc. out of Montreal to sample and analyze the water from both shafts. Ernest Mast, Eng., President and CEO of the Company and a "Qualified Person" within the meaning of National Instrument 43-101, has reviewed and approved the technical information contained in this news release. New Appointment Doré Copper has appointed Emilie Belanger as Manager Environment and Permitting. Ms. Belanger is an environment and sustainability professional with 20 years of experience in the mining industry. She founded Envirosynergie Services in 2014, which was subsequently acquired by GCM Consultants, where she remained until recently as Director of Environmental Services. Prior, she worked at Quebec Lithium as Environmental Superintendent and at Genivar as Assistant Director of the ATNQ (Abitibi-Témiscamingue et le Nord-du-Québec) Environmental Department. Ms. Belanger is very familiar with the “brownfield” assets of Dore Copper having worked for four years in the Environmental Department at Campbell Resources’ operations in the Chibougamau area. About Doré Copper Mining Corp. Doré Copper Mining Corp. is a copper-gold explorer and developer in the Chibougamau area of Québec, Canada. Doré Copper has consolidated a large land package in the prolific Lac Doré/Chibougamau mining camp that has historically produced 1.6 B lbs of copper and 3.2 M oz of gold. In addition, the Corporation has optioned the high-grade Joe Mann gold mine (historical production 1.17 M oz at 8.26 g/t Au). The land package includes 12 former producing mines, deposits and resource target areas within a 60-kilometer radius of the Corporation's 2,700 tpd mill (Copper Rand Mill). The Corporation's current focus is to grow mineral resources and re-develop the high-grade Corner Bay (Cu-Au), Cedar Bay (Au-Cu), and Joe Mann (Au) deposits. The Corporation has resumed its drilling program starting at Corner Bay, which will lead to an updated mineral resource estimate in Q2 2021 and a PEA in H2 2021. For further information, please visit the Corporation's website at www.dorecopper.com or refer to Doré Copper's SEDAR filings at www.sedar.com or contact: Ernest MastLaurie GaboritPresident and Chief Executive OfficerVice President, Investor RelationsPhone: (416) 792-2229Phone: (416) 219-2049Email: firstname.lastname@example.orgEmail: email@example.com Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "forecast", "expect", "potential", "project", "target", "schedule", "budget" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions and includes the negatives thereof. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the timing and ability of the Corporation to receive necessary regulatory approvals, and the plans, operations and prospects of the Corporation and its properties are forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to, actual exploration results, changes in project parameters as plans continue to be refined, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, uninsured risks, regulatory changes, delays or inability to receive required regulatory approvals, health emergencies, pandemics and other exploration or other risks detailed herein and from time to time in the filings made by the Corporation with securities regulators. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ from those described in forward-looking statements, there may be other factors that cause such actions, events or results to differ materially from those anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
The "2021 Isoflavones Market - Size, Share, COVID Impact Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
According to the new market research report "Dark Fiber Market with COVID-19 Impact Analysis by Type (Single Mode Fiber, Multimode Fiber), Network Type (Metro, Long Haul), End User (Internert Service Providers and Telecommunications Industry), Geography - Global Forecast to 2026", published by MarketsandMarkets™, the market size is projected to reach USD 8.7 billion by 2026 from an estimated USD 5.2 billion in 2021, at a CAGR of 11.0% from 2021 to 2026. The rising demand for 5G network is among the factors driving the growth of the dark fiber market.
Trial funded in part by a Maryland Stem Cell Research Fund TEDCO GrantMIAMI, March 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that enrollment criteria for its Phase 1 Acute Respiratory Distress Syndrome (ARDS) RECOVER trial has been expanded to include mild ARDS, in addition to moderate and severe ARDS. Previously, only ARDS patients intubated with an endotracheal tube for positive pressure ventilation were eligible. The protocol amendment allows for the inclusion of milder cases of ARDS patients who present with the need for supplemental oxygen via high flow nasal cannula, partial or nonrebreathing mask, or non-invasive positive pressure mask. The RECOVER Trial is a double-blind, randomized, placebo-controlled study designed to evaluate the safety and efficacy of up to 3 intravenous administrations of either Lomecel-B (allogeneic bone marrow-derived medicinal signaling cells) or placebo in COVID-19 or Influenza-infected ARDS patients. The primary measures of efficacy are functional lung recovery, recovery from infection, inflammatory status, immune status, and lung imaging. “The goal here is to reduce the inflammatory response and to either prevent the need for mechanical support, or to allow these individuals to come off of the ventilator and leave the ICU,” stated Joe G. N. "Skip" Garcia, MD, a world-renowned pulmonologist and professor of medicine at the University of Arizona College of Medicine. ARDS resulting from COVID-19 or Influenza is driven by severe inflammation, called a cytokine storm. This can lead to accumulation of fluid in the lungs and severe tissue damage, and ultimately decreased ability to oxygenate the blood. The most severe cases lead to respiratory failure and the high mortality rate from COVID-19. Longeveron’s Lomecel-B has the potential to reduce the cytokine storm involved in ARDS and thus the possibility to improve clinical outcomes in COVID-19 patients. The RECOVER Trial received a prestigious TEDCO award from the Maryland Stem Cell Research Fund (MSCRF) to help support the Phase 1 study. This is Longeveron’s third TEDCO Award since 2017. Participating clinical centers currently include the Miami VA Health System, University of Maryland Medical Center, and Wake Forest University Hospital. The Company is in the process of expanding the number of participating clinical sites. Any clinical sites or investigators interested in learning more about participating in the phase 1 trial should contact: Kevin Ramdas, MD, MPH, Associate Director, Medical Affairs; firstname.lastname@example.org. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com. Forward-Looking Statements Certain statements in this press release that are not historical facts are forward-looking statements that reflect management's current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Moreover, forward-looking statements in this release include, but are not limited to, statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates, our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Contact:Crescendo Communications, LLCTel: 212-671-1020Email: email@example.com
Callinex Mines Inc. (the "Company" or "Callinex") (TSXV: CNX) (OTC: CLLXF) announces that it has granted 160,000 stock options to its directors, officers and consultants. The options are exercisable at $5.00 per share, subject to certain vesting requirements and expire five years from the date of grant.
LONDON, March 05, 2021 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE:GSL) (the “Company”) announced today that the Company’s Board of Directors has declared a cash dividend of $0.546875 per depositary share, each representing a 1/100th interest in a share of its 8.75% Series B Cumulative Redeemable Perpetual Preferred Shares (the “Series B Preferred Shares”) (NYSE:GSLPrB). The dividend represents payment for the period from January 1, 2021 to March 31, 2021 and will be paid on April 1, 2021 to all Series B Preferred Shareholders of record as of March 25, 2021. About Global Ship Lease Global Ship Lease is a leading independent owner of containerships with a diversified fleet of mid-sized and smaller containerships. Incorporated in the Marshall Islands, Global Ship Lease commenced operations in December 2007 with a business of owning and chartering out containerships under fixed-rate charters to top tier container liner companies. On November 15, 2018, it completed a strategic combination with Poseidon Containers. Global Ship Lease owns 43 containerships, and has contracted to purchase a further seven ships, ranging from 2,207 to 11,040 TEU, with a total capacity (when fully delivered) of 287,336 TEU. 32 ships are Post-Panamax, of which nine are fuel-efficient new-design wide-beam. Adjusted to include all charters agreed, and ships acquired or divested, up to March 3, 2021, the average remaining term of the Company’s charters at December 31, 2020, to the mid-point of redelivery, including options under the Company’s control, was 2.5 years on a TEU-weighted basis. Contracted revenue on the same basis was $892.5 million. Contracted revenue was $1,051.4 million, including options under charterers’ control and with latest redelivery date, representing a weighted average remaining term of 3.1 years. Safe Harbor Statement This press release contains forward-looking statements. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements include statements about the Company's expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "will" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. These forward-looking statements are based on assumptions that may be incorrect, and the Company cannot assure you that the events or expectations included in these forward-looking statements will come to pass. Actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors, including the factors described in "Risk Factors" in the Company's Annual Report on Form 20-F and the factors and risks the Company describes in subsequent reports filed from time to time with the U.S. Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.Investor and Media Contact: The IGB GroupBryan Degnan646-673-9701or Leon Berman 212-477-8438
Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older.1 FLUCELVAX QUADRIVALENT was previously FDA-approved for use in persons four years of age and older. FLUCELVAX QUADRIVALENT will be available as a 0.5ml intramuscular (IM) vaccine per dose for the 2021/22 U.S. influenza season.
SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has closed its previously announced private placement in which the Company sold an aggregate of 1,152,628 Units to certain institutional and accredited investors as follows: (a) 916,316 units at an offering price of $7.07 per unit, consisting of 1 American Depositary Share ("ADS"), a Series A Warrant to purchase an equal number of Units purchased and a Series B Warrant to purchase half the number of Units and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of 1 pre-funded warrant to purchase one ADS, a Series A Warrant to purchase an equal number of Units purchased and a Series B Warrant to purchase half the number of Units. The Series A Warrants have an exercise price of $7.07, subject to adjustments therein. The Series B Warrants have an exercise price equal to $10.60, subject to adjustments therein. The Series A Warrants and the Series B Warrants are exercisable six months from the date of issuance and have a term of exercise equal to five years from the initial exercise date. The Pre-Funded Warrants have an exercise price of $0.001 per full ADS. The Pre-Funded Warrants will be exercisable at any time after the date of issuance upon payment of the exercise price. The aggregate gross proceeds from the offering were approximately $8.15 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
A combination of common medications and treatments can keep some, if not most, COVID-19 patients out of the hospital. That is the information collated from the world's medical literature and practiced by Connecticut physician, H. Robert Silverstein, MD, Medical Director of The Preventive Medicine Center in Hartford.
WOODCLIFF LAKE, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Timber’s Chief Executive Officer John Koconis will present a corporate overview at the virtual 2021 H.C. Wainwright Global Life Sciences Conference being held on March 9-10, 2021. Timber’s presentation will be available to registered conference attendees for on-demand viewing beginning March 9, 2021 at 7:00AM EST via the virtual conference link. Mr. Koconis and Joe Luchese, Chief Financial Officer, will also participate in one-on-one investor meetings with registered conference attendees throughout the conference. About Timber Pharmaceuticals, Inc. Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Form 10-Q filed on August 18, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. For more information, contact: Timber Pharmaceuticals, Inc. John Koconis Chief Executive Officer firstname.lastname@example.org Investor Relations: Stephanie Prince PCG Advisory (646) 863-6341 email@example.com Media Relations: Adam Daley Berry & Company Public Relations (212) firstname.lastname@example.org
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that a supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab was accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for treatment in the second- or third-line setting of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior platinum-based chemotherapy.